"THINK OF IT AS A BIODEGRADABLE T INTERNAL BAND-AID®."
E-Mail YOUR DOCTORS AND ASK WHAT THEY THINK:
Based in suburban Orlando, Florida, Cardiovascular Sciences Inc. (CV Sciences) is a technology company focused on the development of innovative medical products.
CV Sciences is currently developing proprietary technology for the prevention of post-surgical adhesions, and has acquired the rights to an inventory of intellectual properties that include:
• A patented method for treating patients suffering from cardiac trauma, such as ischemic reperfusion injury, heart failure, and bypass surgery, that augments the inotropic effects of ß-adrenergic agents with pyruvate.
• A patented Thromboresistant Coating that prevents blood clot formation on medical devices.
• Four patented aortic pumping catheters.
CV Sciences and the University of Central Florida have entered into an agreement to research and develop post-surgical anti-adhesion materials. The principal investigator, Dr. Kevin Belfield, chairman of the Department of Chemistry, is leading a team to further develop the most effective and efficient anti-adhesion materials. It is expected that the scope of this research will expand and broaden as the Company continues to develop this technology.
"The Human market for post-surgical antiadhesion is estimated at $3 billion in the U.S. and $5 billion globally."
Patented Pyruvate Therapy
CV Sciences has the worldwide marketing and licensing rights for a patented process that provides a novel carioplegia solution containing pyruvate for use in cardiopulmonary bypass surgery.
Patented Aortic Catheters
The Company has acquired the rights to develop and market four patented aortic pumping catheters: an Enhanced Intra-Aortic Balloon Catheter (EIABC), a Removable Left Ventricular Assist Device with an Aortic Support Apparatus, a Coronary Artery Counterpulsation Device and Method, and a Piston-action Intra-Aortic Coronary Assist Device. The new catheter designs overcome the inefficiencies of existing products in the market, and are designed to be application specific, thereby delivering the optimal performance for any given clinical setting.
Patented Thromboresistant Coating
CV Sciences owns the rights to a patented Thromboresistant Coating which has a variety of applications.
-Dr. Larry Hooper (CEO)
is a physician with 30 years experience in the medical field and with a very broad background. Besides a strong clinical background, he has participated in several FDA sanctioned trials as lead site investigator. In the late 1990’s, he was the Chief Flight Surgeon for the U.S. Air Force’s B-2 Stealth Bomber.
-Eric O. Edelmann (President)
is a business development consultant with 35+ years of experience. His clients have included many top Fortune 500 companies.
-Undergraduate degree from Cornell University
-MBA (Marketing and International Business) is from Columbia University Graduate School of Business.
Mr. Edelmann founded Strategic Futures International, a marketing and management consulting firm specialized in serving the long range planning needs of a wide range of industries. Major clients have included Alcoa, American Cyanamid, Becton-Dickinson, DuPont, the FAA, IBM, ITT, Lear Siegler, Monsanto, New Jersey DOT, Owens-Corning, PPG, R.R.Donnelley & Sons, 3M, Time Inc., and the U.S. Postal service, to name only a few. Prior to forming this firm, He was President of Strategic Futures, Inc., a division of Jaakko P?yry Consulting (JPC) Inc. (North America), as well as being a Senior Consultant for Special Projects with this firm.
Estimated Market Cap
13,578,948.54 as of Feb 8, 2008
16,764,134 as of Jan 1, 2008
100,000,000 as of Jan 1, 2008
Number of Share Holders of Record
1,050 as of Jan 1, 2008
2,561,000 as of Jan 1, 2008
OLDE MONMOUTH STOCK TRANSFER CO., INC.
Good DD Links: